Stock Taper
SCREENER COMPARE ANY 2 STOCKS
URGN
UROGEN PHARMA LTD.
NASDAQ
$43.62
▼ DOWN 4.13% (-1.88)

KEY STATISTICS

Market Cap$2.13 B
52w High$50.81
52w Low$15.86
Dividend Yield—
Frequency—
P/E-22.03
Volume580.05K
Shares Out.48.72M

COMPANY

LEADERSHIP

Elizabeth A. Barrett
CHIEF EXECUTIVE
Elizabeth A. Barrett

COMPENSATION 2026

Salary$855,590
Stock Awards$2,122,211
Incentive Plan Pay$516,263
All Other Comp.$42,494
Total$4,310,624

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 4, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
300

PRICE TARGET

Target High$75.00
Target Low$40.00
Target Median$50.00
Target Consensus$53.40

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$90.58M
NOV
5
THU

PRICE

$43.62 ▼ DOWN 4.13% (−$1.88)
$43.50$44.25$45.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM43.62

About UroGen Pharma Ltd.

https://www.urogen.com ↗

UroGen Pharma Ltd. develops innovative therapies for urothelial cancers and diseases, including RTGel-based products like Jelmyto and UGN-102, currently in Phase III trials, through collaborations with Allergan, Agenus, and MD Anderson.

INDUSTRY

Biotechnology

A PRODUCT UROGEN PHARMA LTD. IS KNOWN FOR

Jelmyto® (mitomycin) for pyelocalyceal solution
Jelmyto® (mitomycin) for pyelocalyceal solution

Jelmyto® is the first FDA-approved non-surgical treatment for low-grade UTUC, using UroGen's RTGel® technology to deliver mitomycin directly to the urinary tract, providing a kidney-sparing option in uro-oncology.

COMPETITORS

COMPETITOR
AZN COMPARE
BMY COMPARE
IBRX COMPARE
MRK COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Jelmyto$25.7M $23.82M ▼$21.71M ▼$22.03M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
103
LISTED HERE
23
RANKED BY POSITION SIZE
IWM
0.06% · 1.1M
VTWO
0.05% · 239.2K
FESM
0.14% · 201.2K
SPDW
0.02% · 187.2K
CANC
1.26% · 61.3K
IZRL
1.81% · 54.3K
FFTY
2.88% · 49.3K
ITEQ
1.66% · 43.3K
XRS2.DE
0.06% · 40.7K
GSSC
0.13% · 31.5K
RSSL
0.06% · 20.3K
HY
HYP
1.20% · 19.0K
AVTM
0.02% · 3.6K
IBBQ
0.14% · 3.0K
AI
AIMS
0.13% · 2.6K
AI
AIIQ
0.31% · 2.2K
BIB
0.08% · 1.7K
FLQS
0.14% · 1.4K
WCEO
0.18% · 526
USUE.DE
0.00% · 185
KBFR
0.07% · 185
PCSG
0.23% · 133
RESM
0.06% · 75

INSTITUTIONAL OWNERSHIP

SHARES OWNED
63.88%
HOLDERS
224
TOP 12 OF 224 · RANKED BY POSITION SIZE
Rtw Investments, LP
4.5M sh · $81.7M
Paradigm Biocapital Advisors LP
4.5M sh · $104.77M
Toronto Dominion Bank
3.2M sh · $63.65M
Blackrock, Inc.
2.8M sh · $51.16M
Morgan Stanley
2.6M sh · $60.02M
Kynam Capital Management, LP
2.2M sh · $40.41M
Jefferies Financial Group Inc.
2.2M sh · $39.55M
Blackrock Inc.
2.2M sh · $36.81M
Cowen And Company, LLC
1.8M sh · $22.82M
Silverarc Capital Management, LLC
1.7M sh · $40.72M
Acorn Capital Advisors, LLC
1.7M sh · $30.09M
Sg Americas Securities, LLC
1.7M sh · $29.81M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Robinson James A. Jr.
Purchase · 2.0K shares
2026-08-26
★
DIRECTOR
Robinson James A. Jr.
Sale · 2.0K shares
2026-08-26
★
OFFICER: CHIEF MEDICAL OFFICER
Schoenberg Mark
Sale · 60.7K shares
2026-08-20
★
OFFICER: CHIEF MEDICAL OFFICER
Schoenberg Mark
Sale · 10.0K shares
2026-07-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Guggenheim BUY TD Cowen BUY Oppenheimer OUTPERFORM D. Boral Capital BUY

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
NRIX$26.21COMPARE
KOD$37.72COMPARE
XNCR$26.06COMPARE
ANAB$56.28COMPARE
PHAT$9.18COMPARE
BBOT$8.74COMPARE
OCS$12.21COMPARE